Tanox: TNX-355 demonstrates sustained virologic response in treatment of HIV

By Lisa Kerner

Charlotte, N.C., Aug. 17 - Tanox, Inc. said new data confirm that TNX-355, when used in combination with an optimized background regimen (OBR) of antiretroviral drugs, produced a sustained virologic response in treatment-experienced HIV patients.

The 48-week data, from a phase 2 clinical trial of TNX-355, an advanced humanized monoclonal antibody, was presented at the 2006 International AIDS Conference in Toronto.

Tanox reported that the study met its primary endpoint of mean viral load reduction from baseline at week 24.

Depending on the TNX-355 dose, the percentage of patients experiencing a viral-load reduction of at least 0.5 log10 at week 48 was 44% and 39%, compared to 11% of patients in the placebo group.

In the 82-patient trial, a clear trend was observed in a viral load reduction of at least 1.0 log10, or a 90% decrease of HIV in the bloodstream. Depending on the dose, the percentage of patients in each group experiencing this viral-load reduction was 37% and 32%, compared to 11% in the placebo group.

"These results show that TNX-355-based regimens were able to suppress viral loads for nearly one year in a considerable number of treatment-experienced patients in the study," medical director Stanley Lewis said in a company news release.

"The durable response demonstrated by TNX-355 plus OBR, compared to OBR alone in this patient population, indicates that TNX-355 could be a valuable therapy for patients who are faced with limited treatment options."

Tanox also presented a phase 2 study oral abstract highlighting in vitro findings of TNX- 355's activity against enfuvirtide-resistant HIV.

Houston-based Tanox develops biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.